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Interphase fluorescence in situ hybridization improves
the detection of malignant cells in effusions from breast
cancer patients
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Summary In diagnostic evaluation of effusions, difficulties are encountered when atypical reactive mesothelial cells have to be differentiated
from malignant cells. We tested the impact offluorescence in situ hybridization (FISH) to identify metastatic cells in breast cancer effusions by
detection of numerical chromosomal changes. Pleural and ascitic fluid samples (n=57) from 41 breast cancer patients were concomitantly
evaluated by routine cytology and FISH, using centromere-specific probes representing chromosomes 7, 11, 12, 17 and 18. After setting
stringent cut-off levels deduced from non-malignant control effusions (n=9), the rates of cells with true aneuploidy were determined in each
effusion sample from breast cancer patients. The occurrence of aneuploid cells, as detected by FISH and indicative of malignancy, was
correlated with the cytological findings. Routine cytology revealed malignancy in 60% of effusions. Using FISH, aneuploid cell populations
could be observed in 94% of cytologically positive and in 48% of cytologically negative effusions, thus reverting diagnosis to malignancy. To
confirm malignancy in cases with a low frequency of aneuploid cells, two-colour FISH was additionally performed and indeed showed
heterogeneous chromosomal aneuploidy within single nuclei. We conclude that FISH is a valuable tool in the diagnosis of malignancy and
may serve as an adjunct to routine cytological examination, as demonstrated here for breast cancer effusions.
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Interphase cytogenetics by fluorescence in situ hybridization has
gained broad use in basic research to delineate common chromo-
somal abnormalities in haematological malignancies and solid
tumours. However, there are only few reports describing a poten-
tial clinical application of FISH with diagnostic and prognostic
significance (Escudier et al, 1993; Taylor et al, 1993; Bandyk etal,
1994; Drach et al, 1995a; Tanner et al, 1995). In previous work
from our laboratory, evidence was obtained that chromosomal
abnormalities by FISH are present in cancerous specimens from
all breast cancer patients studied (Fiegl et al, 1995); aneuploidy
was also identified in cytologically negative effusions from breast
cancer patients. This is of interest as cytological diagnosis of
malignancy in effusions from cancer patients is hampered because
of difficulties in differentiating malignant cells from reactive
mesothelial cells (Staff and Sherman, 1991).
The aim of this study was to test the usefulness of FISH as a
complementary diagnostic tool for detection of malignant cells.
Thus, we (1) determined theoccurrence ofaneuploidy forchromo-
somes 7, 11, 12, 17 and 18 in effusions from breast cancer patients,
(2) correlated these findings with concomitantly achieved cytolog-
ical diagnosis and (3) investigated whether background non-
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Fifty-seven consecutive effusion specimens (34 pleural and 23
ascitic) from 41 breast cancer patients and nine effusions (four
pleural and five ascitic) from patients with non-malignant disease
were subjected to routine diagnostic evaluation (haematoxylin-
eosin, papanicolau, giemsa stains) and to FISH studies using
centromeric probes for five chromosomes. All breast cancer
patients (aged between 41 and 85 years, median 58 years) were
considered as clinical stage IV; the lag time from first diagnosis of
breast cancer to punctation ofeffusion ranged from 0.5 to 22 years
(median 4 years). In ten cases (24%), development ofeffusion was
the first sign of generalization. An aliquot of 50 ml of the effusion
specimens was submitted to the Department ofPathology for cyto-
logical evaluation, and at least 1500 nucleated cells per slide were
screened after preparation ofthree cytospins from each sample.
FISH procedures
Depending on availability and cellular density by rapid staining
(Diff. Quick), cells from 200-2000 ml of effusion fluid were
gained by centrifugation, and, in case ofmacroscopic blood conta-
mination, by gradient separation (Ficoll, n=7). Pelleted effusion
cells were washed twice in phosphate-buffered saline (PBS), fixed
in methanol-acetic acid (3:1, v/v) and stored at-80° C.
Directly fluorescence-labelled a-satelliteprobes (eitherSpectrum-
green or Spectrum-orange; Imagenetics, Framingham, MA, USA),
specific for the centromeric regions of human chromosomes 7, 11,
12, 17 and 18, were applied, following the protocol described by
Drach et al (1995b). In 13 effusions, chromosomes 11 and 17 were
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Table 1 FISH results of pleural and peritoneal fluid samples from patients with non-malignant disease (n-9)
Signal number per nucleus
Chromosome 1 2 3 4 5 6
7 5.11 + 1.08 94.41 ± 1.11 0.23_0.11 0.23±0.37 0 0.02±0.05
11 5.96 ± 1.88 93.49 + 1.60 0.20 ± 0.20 0.33 ± 0.52 0.02 ± 0.05 0
12 5.30 + 1.39 93.85 ± 0.92 0.52 ± 0.38 0.33 + 0.47 0 0
17 7.59 + 2.28 91.73 ± 1.88 0.34 ± 0.29 0.34+ 0.66 0 0
18 7.45 + 1.35 92.00 + 0.98 0.31 + 0.31 0.24 + 0.44 0 0
Data are given as mean percentage ± s.d. of centromeric signal numbers. At least 1000 nuclei were analysed per sample and chromosome. Mean percentages
+ 3 s.d. were calculated for definition of the cut-off levels.
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Table 2 Classification of 57 effusions from breast cancer patients by cytology
and FISH
Aneuploidy ratea for chromosome
No. Siteb cc FISHc
1 P Neg Neg
2 p Neg Neg
3 p Neg Neg
4 Ph Neg Neg
5 p Neg Neg
6 p Neg Neg
7 A Neg Negh
8 A Neg Neg
9 Ai Neg Neg
10 Ai Neg Neg
11 Ai Neg Neg
12 Ai Neg Neg
13 p Pos Pos
14 p Pos Pos
15 p Pos Pos
16 p Pos Pos
17 p Pos Pos
18 p Pos Pos
19 p Pos Pos
20 p Pos Pos
21 Ph Pos Posp
22 p Pos Posp
23 p Pos Pos
24 p Pos Posp
25 pd Pos Pos
26 p Pos Pos
27 p Pos Pos
28 p Pos Pos
29 pk Pos Pos
30 pk Pos Pos
31 p Pos Pos
32 pi Pos Pos
33 pi Pos Pos
34 pi Pos Posp
35 A Pos Pos
36 A Pos Pos
37 Af Pos Pos
38 Ag Pos Pos
39 Ag Pos Pos
40 Ag Pos Pos
41 Ag Pos Pos
42 A Pos Pos
43 Ad Pos Pos
44 A Pos Pos
45 p Pos Neg
46 p Pos Negq
47 p Neg Pos
48 pe Neg Pos
49 pm Neg Pos
50 pm Neg Pos
51 Ae Neg Pos
52 Ae Neg Pos
53 Af Neg Pos
54 Af Neg Pos
55 A Neg Pos
56 A Neg Posp
57 Ai Neg Posp





























































57.1 3.2n 39.5 17.5 40.4
6.5 0 4 0 0
4.3 5.3 3 1.9 7.5
1 2.8 0 1 1.5
0 13.6 5.9 4.4 0
1.2 2.2 1.2 79.1 n 83'
31.1 77.3 39.1 2.9 0.8
9.9 11 1.1 1.8 3.1
0.8 21 2.1 3.9 0.5
1.2 15.1 1.1 8.9 0
3.8 34.6 0 7.4 0
0 1.5 3.3 6.9 16.2
0 6.2 0 3.3 0
62.8 72.1 65.4 68.4 58.7
0 0 0 0 0
0 0 0 0 0.5
0 5.8 0.7 1.8 0.8
0 3.8 0.6 80" 0
12 16.4 17.6 0 33.5
11.6 4.4 9.4 3.9 9.9
0 9.1 3.8 67.1" 0
5.2 1.8 0 69.2n 1.4
64.1 72.8 60.2 5.8 1
56.8 72.9 53.5 0.8 0
0.5 6.9 1 1 0
0 0.5 0.3 0 0.6
0.5 0 1.2 0 0
aAneuploidy rate is the sum of percentages of monosomy and . trisomy
above cut-off. bp, pleural effusion; A, ascitic effusion. cCytological and FISH
classification of effusion. Neg, negative; Pos, positive.- Effusions from the
same patient. nPredominantd-m monosomy. PResults confirmed by two-colour
FISH. qClassification according to two-colour FISH; results of single-
hybridization experiments could not be confirmed.
targeted with biotin- and digoxigenin-labelled probes (Fiegl et al,
1995), which were obtained from Oncor(Gaithersburg, MD, USA),
and detection was accomplished using FITC-conjugated avidin and
anti-digoxigenin rhodamine respectively. In agreement with our
previous experience, the confidence intervals forcontrols were iden-
tical forboth types ofprobes (Escudier etal, 1993).
For two-colour studies, DNA probes representing two chromo-
somes and labelled with different fluorochromes were combined.
In control effusions, chromosomes 11 and 18 were targeted for
two-colour FISH experiments; in effusions from breast cancer
patients, centromeric probes were chosen depending on the results
ofsingle hybridization experiments.
Analysis by fluorescence microscopy
Fluorescence signals of at least 1000 nuclei from control effusions
and 200-800 nuclei from breast cancer effusions were scored, with
high-number cell counting in samples with low frequency of aneu-
somic cells (Kibbelaar et al, 1993). An Olympus AH-3 microscope
with a 100 x planar objective was used for signal analysis, and the
stringent criteriaproposedbyHopman et al(1988) wereapplied. The
portion of zero-spot cells (inversely correlated with hybridization
efficiacy) was below 1% in all control and breast cancereffusions.
All cells in a field were scoredexcept forgranulocytes; lympho-
cytes were not omitted from evaluation as nuclear shape of
lymphoid cells may resemble that ofbreast cancer cells (Johnston,
1985). Signal analysis was done withoutknowledge ofcytological
results.
Definition ofaneuploidy rate
For an unequivocal definition of true aneuploidy in breast cancer
effusions, mean percentages + 3 s.d. of control cells with non-
disomic signal numbers were set as cut-off levels (Bentz et al,
1993; Drach et al, 1995a; Fiegl et al, 1995). Percentages of mono-
somic, trisomic and up to hexasomic cells in breast cancer effu-
sions were thus corrected for background aneuploidy, as derived
from control effusions (Table 1). Cells with more than six signals
were considered as unambiguously aneuploid. To quantitate truly
aneuploid cells in breast cancer effusions, aneuploidy rate was
calculated as the sum ofpercentages of monosomy and > trisomy
above the cut-offlevels.
RESULTS
Observation of non-diploid cells in control effusions
By means of extensive cell counting, rare aneusomic cells were
found in control effusions from nine patients with non-cancerous
diseases (Table 1). Percentages of trisomic cells were in accor-
dance with previous observations in normal lymphocytes (Fiegl et
al, 1995; Herrington et al, 1995). However, a significant propor-
tion of mesothelial cells, distinguished by size and shape, exhib-
ited tetrasomy for all chromosomes examined; in three effusions
also pentasomy and/or hexasomy was observed. As detected by
two-colour FISH, there was equality in copy numbers for chromo-
some 11 and 18 in these mesothelial cells, indicative ofpolyploidy
rather than numerical changes of single chromosomes (not
shown), being in accordance with previous reports on polyploidy
in mesothelial cells (Bousfield et al, 1984; Biesterfeld et al, 1994).
Cut-off levels were calculated as outlined in the methods
section.
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Aneuploidy for chromosomes 7, 11, 12, 17 and 18 in
cytologically malignant breast cancer effusions
Of 57 consecutive effusions, 34 (60%) were diagnosed as malig-
nant following routine cytological procedures, frequency being in
line with previous reports (Leuallen and Carr, 1955; Banerjee et al,
1994). Pleural effusions were cytologically positive in 71%,
whereas malignancy could be found in 43% of ascitic effusions.
In order to define the frequency of aneuploidy in cytologically
positive effusions, FISH using centromeric probes representing
chromosomes 7, 11, 12, 17 and 18 was performed. Of the 34 cyto-
logically positive effusions, 28 contained aneusomic cells in more
than 5% above the defined cut-off and five effusions in a
percentage below 5%. In one effusion, no aneuploidy was detected
by FISH using these five centromeric probes, as shown in Table 2.
The extent of aneuploidy in all effusions is listed in Table 2,
using an index based on the signal counting results (aneuploidy
rate). To confirm diagnosis of malignancy in the five effusions
with aneuploidy rates below 5%, two-colour FISH was performed.
Heterogeneous chromosomal abnormalities within single cells
were indeed demonstrated in four cases (Figure 1). One of the
five effusion specimens was classified as being non-malignant
according to two-colour FISH. Thus, 32 of the 34 cytologically
positive effusions (94%) fulfilled our criteria of malignancy, as
detected by FISH.
The counting results concerning chromosomes 11 and 17 for 13
effusions were detailed in our previous report (Fiegl et al, 1995).
In the extended series presented in this study, all FISH-positive
cases showed predominantly gain for chromosomes 7, 11 and 12;
however, predominance of monosomy 17 in four cases (11% of
effusions with aneuploidy for chromosome 17), of monosomy 18
in two cases (8% of effusions positive for chromosome 18) and of
monosomy 11 in one case was observed. Furthermore, tumour cell
heterogeneity for all five chromosomes was detected, mostly with
a wide range of centromeric signal numbers.
The constant presence of aneuploidy in cytologically positive
effusions suggests that this finding can be used as an indicator of
malignancy in diagnostic procedures.
FISH detects aneuploid cells in cytologically negative
effusions
Twenty-three cytologically negative effusions were examined by
FISH for the potential occurrence of malignancy, undetectable by
cytological criteria only. Interphase cytogenetics, including two-
colour FISH, revealed true aneuploidy in 11 ofthese effusion spec-
imens (48%). Combined aneuploidy rates for all five chromosomes
ranged from 0.6% to 80% (median 11.6%).
Combination of centromeric probes for chromosomes 7 and 11
represented the most successful combination of two probes as 42
out of the 43 FISH-positive effusions were detected. In 12 effu-
sions, neither FISH nor cytology yielded positivity, giving evi-
dence of a reactive genesis of effusions, e.g. portal hypertension
owing to metastasis to the liver.
Analysing results according to effusion site, FISH improved
diagnostic sensitivity in the case ofascitic effusions (74% positivity
vs 43% positivity by routine cytological evaluation; P< 0.05, using
the X2-test). Nevertheless, aneuploid cell populations could also be
demonstrated in four cytologically negative pleural effusions (76%
positivity vs 71% cytological positivity; P=NS). When considering
all positive effusions (by FISH and/or cytology; n=45), malignancy
could be detected in 96% (n=43) byFISH alone, whereas positivity
was diagnosed in only 76% (n=34) by routine cytological criteria
(P<0.01).
DISCUSSION
This is the first systematic study investigating interphase cyto-
genetics as a tool in the evaluation of breast cancer effusions for
malignancy. Cancerous cells in effusions from breast cancer patients
are detectable in about 50% using routine cytology (Banerjee et al,
1994; Leuallen et al, 1955). Difficulties are encountered when atyp-
ical reactive mesothelial cells have to be differentiated from malig-
nant cells (Starr et al, 1991). Thus, considerable effort has been
undertaken to improve tumour cell detection in effusions from
cancer patients by means ofimmunocytochemistry, DNA cytometry
and metaphase cytogenetics (Bousfield et al, 1985; Loy et al, 1990;
Gioanni et al, 1991; Osinaga et al, 1992; Athanassiadou et al, 1994;
Joseph et al, 1995). Because of problems concerning sensitivity
and/or specificity and technical limitations, these methods have not
gained broad clinical significance in diagnostic evaluation of effu-
sions. However, as the Ber-EP4 antibody distinguishes between
epithelial and mesothelial cells (Latza et al, 1990; De-Angelis et al,
1992; Illingworth et al, 1994), it would be interesting to compare
FISH analysis with an immuno-cytochemical approach using the
Ber-EP4 antibody, either alone or as part of a panel of antibodies.
In breast cancer, no specific genetic alteration is present which
would allow screening for an isolated chromosomal change.
However, disease progression leads to accumulation of chromo-
somal alterations, resulting in complex karyotypes (Heim et al,
1988; Dutrillaux et al, 1991; Trent et al, 1993), thus enabling inter-
phase cytogenetics to be used in tumour cell detection when a panel
of centromeric probes is applied. Indeed, aneuploid cell populations
could be demonstrated with FISH in 43 of the 57 effusions in our
series (75%), and, more interestingly, in 11 ofthe 23 (48%) effusions
with a negative cytological diagnosis. FISH results ofcells separated
over a Ficoll-Hypaque gradient (seven effusions) reflected the
results of the whole series, thus excluding a major influence of cell
enrichment by Ficoll on the data in this subset of effusions.
In two cytologically positive effusions, aneuploid cells could not
be detected by interphase cytogenetics using five centromeric
probes. Use of a larger panel of FISH probes for screening might
reveal chromosomal changes in these cases too, as breast cancer is a
genetically extremely heterogeneous disease with aneuploidy
detected in the vast majority ofcases (Beerman et al, 1991; Teixeira
et al, 1994; Fiegl et al, 1995; Pandis et al, 1995). On the other hand,
enrichment ofcells expressing epithelial markers by flow cytometry
and consecutive FISH analysis might improve the detection limit of
interphase cytogenetics in the case of rare breast cancer cells.
For FISH studies, adequate control material is crucial as clonal
chromosomal changes may physiologically occur in different non-
neoplastic cells (Richard et al, 1993; Casalone et al, 1995), and
FISH-inherent artifacts may also contribute to background non-
diploidy. Our results of cells with monosomic and trisomic signals
in control effusions are in good agreement with results obtained by
other investigators (Eastmond et al, 1995; Herrington et al, 1995).
It is generally believed that overlapping signals are the main
reason for monosomy in control cells, whereas non-specific
binding and signal-splitting is thought to be responsible for the
trisomy observed in these cases. We also observed rare tetrasomic
cells in our control effusions, propably due to the occurrence of
polyploid mesothelial cells. By setting stringent cut-off levels,
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background non-diploidy was differentiated from aneuploidy,
clearly indicating malignancy.
In the effusions with low but significant aneuploidy rates (e.g.
effusion sample 22), the percentage ofcounted nuclei with three or
more signals was always more than 1%, which is considered as the
lower detection limit of FISH analysis (Kibbelaar et al, 1993). To
validate specificity, all effusions with an aneuploidy rate below 5%
were reviewed using two-colour FISH. Hereby, malignancy in six
samples could be confirmed, whereas the finding of polyploid
cells only (similar to controls) in two of the reviewed effusions
suggested a rather reactive origin.
Development of effusion occurs in 50% of breast cancer
patients (Raju and Kardinal, 1981). In this study, FISH was shown
to be suitable for detection of malignancy in effusions and to
improve sensitivity ofdiagnosis at high specificity. This may be of
great value, especially in the 20% of cases in which effusion is the
only sign of recurrence (Raju and Kardinal, 1981; as shown in our
series also) and other causes of fluid generation need to be
excluded. As anti-tumour therapy requires reliable diagnosis of
malignancy, (micro)-metastasis detection by FISH may lead to
rapid initiation ofadequate treatment.
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